• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Transcription factor Oct4 promotes osteosarcoma by regulating lncRNA AK055347.
Authors: Fan H, Liu G, Zhao C, Li X, Yang X Abstract Osteosarcoma is the most common primary bone tumor in children and adolescents, typically presenting with a poor prognosis. Octamer-binding transcription factor 4 (Oct4) protein, encoded by the POU class 5 homeobox 1 gene, is important in maintaining self-renewal of pluripotent stem cells, and is closely associated with cancer. However, its role in osteosarcoma remains to be elucidated. The present study observed Oct4 was markedly increased in osteosarcoma cell lines and in human osteosarcoma tissue samples. Following Oct4 downregulation by small interfering RNA ...
Source: Oncology Letters - January 28, 2017 Category: Cancer & Oncology Tags: Oncol Lett Source Type: research

Targeting specificity protein 1 transcription factor and survivin using tolfenamic acid for inhibiting Ewing sarcoma cell growth
SummaryTranscription factor Specificity protein  1 (Sp1) and its downstream target survivin (inhibitor of apoptosis protein), play major roles in the pathogenesis of various cancers. Ewing Sarcoma (ES) is a common soft tissue/bone tumor in adolescent and young adults. Overexpression of survivin is also linked to the aggressiveness and poor prog nosis of ES. Small molecule Tolfenamic acid (TA) inhibits Sp1 and survivin in cancer cells. In this investigation, we demonstrate a strategy to target Sp1 and survivin using TA and positive control Mithramycin A (Mit) to inhibit ES cell growth. Knock down of Sp1 using small interf...
Source: Investigational New Drugs - December 25, 2016 Category: Drugs & Pharmacology Source Type: research

Crizotinib-induced antitumour activity in human alveolar rhabdomyosarcoma cells is not solely dependent on ALK and MET inhibition
Conclusions: These results provide a further insight into the molecular mechanisms affected by crizotinib in ARMS cells inferring that it could be a useful therapeutic tool in ARMS cancer treatment.
Source: Journal of Experimental and Clinical Cancer Research - October 6, 2015 Category: Cancer & Oncology Authors: Francesca MegiorniHeather McDowellSimona CameroOlga MannarinoSimona CeccarelliMilena PaianoPaul LostyBarry PizerRajeev ShuklaAntonio PizzutiAnna ClericoCarlo Dominici Source Type: research

Abstract 663: Targeting autophagy potentiates the anti-tumoral action of crizotinib in ALK-positive anaplastic large cell lymphoma
ALK (Anaplastic Lymphoma Kinase)-positive Anaplastic Large Cell Lymphoma (ALCL) occurs predominantly in children and young adults. Their chemotherapeutic treatment leads to a 5-year overall survival amounted to 70-80%. The tumor relapses are often very aggressive and lethal and their underlying mechanisms are unknown. Therefore, there is still a need to improve current therapy. Crizotinib is the most advanced ALK tyrosine kinase inhibitor already used in clinics for ALK-associated lung cancers. However, mechanisms of escape to crizotinib have been reported in cell lines and patients submitted to continuous crizotinib treat...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: MITOU, G., FRENTZEL, J., LAMANT, L., MEGGETTO, F., ESPINOS, E., CODOGNO, P., BROUSSET, P., GIURIATO, S. Tags: Experimental and Molecular Therapeutics Source Type: research

Systematic screening identifies dual PI3K and mTOR inhibition as a conserved therapeutic vulnerability in osteosarcoma.
CONCLUSIONS: The approaches described here have identified dual inhibition of the PI3K/mTOR pathway as a sensitive, druggable target in OS and provide rationale for translational studies with these agents. PMID: 25862761 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - April 10, 2015 Category: Cancer & Oncology Authors: Gupte A, Baker E, Wan SS, Stewart E, Loh A, Shelat AA, Gould CM, Chalk A, Taylor S, Lackovic K, Karlstrom A, Mutsaers A, Desai J, Madhamshettiwar PB, Zannettino AC, Burns C, Huang DC, Dyer M, Simpson KJ, Walkley C Tags: Clin Cancer Res Source Type: research

Pages: 1  2